Dr Catherine Terret, medical oncologist at the CLB, explains the various stages in the process of validating therapeutic molecules.

Dr Maren Koban, from Merck and part of the EU-X-CT initiative, gives a pharmaceutical perspective on cross-border access to clinical trials.

Dr Teodora Lalova-Spinks gives an overview of cross-border access to clinical trials and patient empowerment.

Learn more about DRUP-like clinical trials from Dr Bettina Ryll

Learn more about medical and biological innovations in cancer patient care from Centre Léon Bérard, a specialized oncology institute in Lyon

Interview with Dr Sylvain Besle, sociologist at CLB, about sociological aspects influencing patient access to clinical trials.

Dr Louis Larrouquere, oncologist specializing in cerebral oncology at CLB, talks about frequency of brain tumors and their treatment.

Interview with Dr Armelle Vinceneux, oncologist specializing in urological oncology at the Centre Léon Bérard, about urological cancer.

Dr Katriina Jalkanen, medical oncologist and PI of FINPROVE, talks about molecular testing & the Finnish DRUP-like trial FINPROVE.

Learn more about European health organisation with this mini-series dedicated to the topic of cross-border access and the continuity of care

Interview with Dr Ingrid Klingmann, Chairman of the Board of the European Forum for Good Clinical Practice.

Warnyta Minnaard shares her experience of Cancer of Unknown Primary and advocates for the importance of patient advocacy associations.

Bettina Ryll, founder of the Melanoma Patient Network Europe, presents why DLCTs are relevant for patient advocacy groups.

Bringing together cancer researchers, clinicians, and patients, the CGI-Clinics project focuses on improving precision medicine in oncology.

Dr Antony Ceraulo, medical oncologist and hematologist at IHOPE, Lyon, talks about molecular profiling of pediatric cancer patients.

Le Dr Antony Ceraulo, oncologue et hématologue à l'IHOPE de Lyon présente les analyses moléculaires en pédiatrie

Webinar: Advantages and limitations of precision oncology in clinical practice - talk by oncologist Åslaug Helland, Oslo University Hospital

Webinar: Advantages and limitations of precision oncology in clinical practice - talk by Hans Gelderblom, LUMC + PCM4EU coordinator.

Webinar: Advantages and limitations of precision oncology in clinical practice with Dr Małgorzata Oczko-Wojciechowska

Webinar: Advantages and limitations of precision oncology in clinical practice - talk by Ebba Hallersjö Hult, Vision Zero Cancer, Sweden.

How is therapeutic orientation of patients in early-phase therapeutic clinical trials organized? Interview with oncologist Catherine Terret.

How are patients in therapeutic clinical trials organized and supervised? Interview with oncologist Catherine Terret, Centre Leon Berard.

What happens to patients after they leave a therapeutic clinical trial? Interview with medical oncologist Catherine Terret, CLB.

How is oncology healthcare organized to facilitate patient access to clinical trials in France? Talk with oncologist Catherine Terret, CLB.

Patient podcasts for diagnostics and cancer treatment with Pawel Wiechno.

Hans Gelderblom, coordinator of the PCM4EU project, talks about the PCM4EU initiative.

Patient podcast for diagnostics and cancer treatment with Pawel Rogala, medical oncologist.

Patient podcast for diagnostics and cancer treatment with Pawel Krawczyk

Patient podcast for diagnostics and cancer treatment with Maviesz Biolzinski

Patient podcast for diagnostics and cancer treatment with Mateusz Polaczek

Patient podcast for diagnostics and cancer treatment with Lucjan Wyrwicz

Patient podcast for diagnostics and cancer treatment with Andrzej Tysarowski

Dr Mateusz Polaczek, from Maria Sklodowska-Curie National Research Institute of Oncology, presents the adjuvant therapies in lung cancer.

P. Rutkowski, Maria Sklodowska-Curie National Institute for Oncology, reviews the status of targeted therapies for soft tissue sarcomas.

Do you want to learn about the application of AI for health? Loic Verlingue, Centre Leon Berard, presents valuable AI models.

Hans Gelderblom, medical oncologist & researcher from LUMC, talks about clinical research and pharmacogenetics and pharmacotherapy.

Andrew Evans' story: a bioinformatician who became a patient involved in development of cancer-fighting technologies & patient activities.

Exclusive interview with F. Pignatti, Director of oncology and haematology at EMA, on the approval process for new therapeutic molecules

Find out more about the activities of the European Medicines Agency as part of the European DARWIN project. Interview with F. Pignatti, EMA.

Pierre Saintigny introduces patients to the different treatments and therapies available in precision oncology.

Prof. Kjetil Taskén, Oslo University Hospital, talks about the precision cancer medicine initiative in Norway.

Early detection of cancer is important. Pierre Saintigny, Centre Leon Berard, talks about recent research within the field of oral cancer.

Learn more about cross-boarder access to clinical trials: Interview with Véronique Bontridder, a Belgian patient in a French trial.

Sahar Van Waalwijk Van Doorn Khosrovani, pharmacist and PhD, explains the reimbursement methodology of DRUP-like clinical trials.

Learn more about the Dutch funding model to reduce inequality of access to Molecular Tumour Boards.

How does artificial intelligence contribute to digital health? Hugues Berry explains AI projects through mathematics and bioinformatics.

Are you familiar with the applications of artificial intelligence within the field of health? Learn more from Hugues Berry, Inria, France.